Lyell Immunopharma (LYEL) Operating Leases (2020 - 2025)
Lyell Immunopharma (LYEL) has disclosed Operating Leases for 6 consecutive years, with $41.9 million as the latest value for Q4 2025.
- Quarterly Operating Leases fell 17.79% to $41.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.9 million through Dec 2025, down 17.79% year-over-year, with the annual reading at $41.9 million for FY2025, 17.79% down from the prior year.
- Operating Leases hit $41.9 million in Q4 2025 for Lyell Immunopharma, down from $53.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $68.8 million in Q1 2022 to a low of $41.9 million in Q4 2025.
- Historically, Operating Leases has averaged $58.3 million across 5 years, with a median of $58.6 million in 2023.
- Biggest five-year swings in Operating Leases: skyrocketed 30.8% in 2021 and later fell 17.79% in 2025.
- Year by year, Operating Leases stood at $66.6 million in 2021, then dropped by 5.22% to $63.2 million in 2022, then decreased by 9.93% to $56.9 million in 2023, then decreased by 10.37% to $51.0 million in 2024, then decreased by 17.79% to $41.9 million in 2025.
- Business Quant data shows Operating Leases for LYEL at $41.9 million in Q4 2025, $53.1 million in Q3 2025, and $46.6 million in Q2 2025.